Literature DB >> 26441207

Prognostic significance of the EGFR pathway in nasopharyngeal carcinoma: a systematic review and meta-analysis.

Marc L Ooft1, Weibel W Braunius2, Paulien Heus3, Inge Stegeman2, Paul J van Diest1, Wilko Grolman2, Charlotte I Zuur4, Stefan M Willems1.   

Abstract

OBJECTIVE: To evaluate the prognostic impact of the EGF receptor (EGFR) pathway molecules and assess their clinical usefulness.
METHODS: We conducted a systematic review. Pubmed and EMBASE were searched January 2014. The prognostic relevance of EGFR, JAK, PI3K, PIK3CA, STAT3, STAT5, PTEN, AKT, mTOR, GRB2, SOS, RAF, RAS, MAPK, ERK, MEK and CCND1 in nasopharyngeal carcinoma was assessed. The outcomes considered were overall survival, disease-free survival and tumor-node-metastasis stage. Twenty-two studies were included. Risk of bias was evaluated. Meta-analysis for which pooled hazard ratios and 95% CIs were calculated.
CONCLUSION: EGFR overexpression predicts a worse overall survival and disease-free survival in nasopharyngeal carcinoma, but no specific causal pathway molecule could be identified.

Entities:  

Keywords:  EGFR; cancer; epidermal growth factor receptor pathway; meta-analysis; nasopharyngeal cancer; nasopharyngeal carcinoma; outcome; prognosis; review; survival

Mesh:

Substances:

Year:  2015        PMID: 26441207     DOI: 10.2217/bmm.15.68

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  13 in total

1.  Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis.

Authors:  Xuanchang Qi; Xuechang Li; Xiuxia Sun
Journal:  Tumour Biol       Date:  2016-02-24

2.  Effects of miR-144 on the sensitivity of human anaplastic thyroid carcinoma cells to cisplatin by autophagy regulation.

Authors:  Jing Liu; Liguo Feng; Haitao Zhang; Jin Zhang; Yanyan Zhang; Shujing Li; Long Qin; Ziyao Yang; Jianxia Xiong
Journal:  Cancer Biol Ther       Date:  2018-03-26       Impact factor: 4.742

3.  Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience.

Authors:  Shuping Xu; Mayra Ramos-Suzarte; Xianhong Bai; Binghe Xu
Journal:  Oncotarget       Date:  2016-05-31

Review 4.  Cyclooxygenase-2 expression is positively associated with lymph node metastasis in nasopharyngeal carcinoma.

Authors:  Gui Yang; Qiaoling Deng; Wei Fan; Zheng Zhang; Peipei Xu; Shihui Tang; Ping Wang; Jun'e Wang; Mingxia Yu
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

5.  Circular RNA Hsa_circ_0066755 as an Oncogene via sponging miR-651 and as a Promising Diagnostic Biomarker for Nasopharyngeal Carcinoma.

Authors:  Jian Wang; Jinyu Kong; Zhong Nie; Diansen Chen; Jun Qiang; Wanqin Gao; Xiaojie Chen
Journal:  Int J Med Sci       Date:  2020-06-15       Impact factor: 3.738

6.  Intensity-modulated radiotherapy plus nimotuzumab with or without concurrent chemotherapy for patients with locally advanced nasopharyngeal carcinoma.

Authors:  Jianfeng Huang; Qinzhou Zou; Danqi Qian; Leyuan Zhou; Bo Yang; Jianjun Chu; Qingfeng Pang; Kewei Wang; Fuzheng Zhang
Journal:  Onco Targets Ther       Date:  2017-12-08       Impact factor: 4.147

7.  Nasopharyngeal Carcinoma Protein Interaction Mapping Analysis via Proteomic Approaches

Authors:  Mona Zamanian Azodi; Majid Rezaei Tavirani; Mostafa Rezaei Tavirani; Reza Vafaee; Mohammad Rostami-Nejad
Journal:  Asian Pac J Cancer Prev       Date:  2018-03-27

8.  Radiosensitivity enhancement by combined treatment of nimotuzumab and celecoxib on nasopharyngeal carcinoma cells.

Authors:  Jianfeng Huang; Xiaopeng Yuan; Qingfeng Pang; Haowen Zhang; Jiahua Yu; Bo Yang; Leyuan Zhou; Fuzheng Zhang; Fenju Liu
Journal:  Drug Des Devel Ther       Date:  2018-07-16       Impact factor: 4.162

9.  Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report.

Authors:  Jun Jin; Jiahao Du; Yanwei Wu
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

10.  Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells.

Authors:  Ming-Ying Lan; Yen-Bin Hsu; Ming-Chin Lan; Jyh-Ping Chen; Yu-Jen Lu
Journal:  Int J Nanomedicine       Date:  2020-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.